The Changing Face of Primary Immunodeficiency: Improving Diagnosis and Access to Treatment for All Patients

Faculty

Antoine Azar, MD
Division of Allergy and Clinical Immunology
Johns Hopkins University
Baltimore, MD
Mark Ballow, MD
Division of Allergy & Immunology
Morsani College of Medicine
University of South Florida
St. Petersburg, FL

Statement of Need

Patients living with primary immunodeficiency (PI) disorders face prolonged or severe infections that pose significant challenges to daily life. While infectious PI phenotypes have garnered the most visibility, this focus has left noninfectious variants underrecognized and delayed in diagnosis, leading to poorer outcomes – especially among vulnerable pediatric patients. As early detection is crucial for effective intervention, clinicians, pediatricians, immunologists, and multidisciplinary teams must be equipped with the knowledge to identify noninfectious PI phenotypes swiftly. Addressing social drivers of health and closing care gaps are likewise essential in delivering equitable and compassionate treatment for patients with PI.

In this CME Outfitters Snack, expert faculty will assess the various presentations of PI, including atypical presentations, to improve PI recognition and diagnosis. Faculty will differentiate among the immunoglobulin therapies available for the treatment of PI that enable optimal, personalized care as well as demonstrate how to develop multidisciplinary, team-based strategies to address disparities in care among patients with PI.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the various presentations of PI, including atypical presentations, to improve PI recognition and diagnosis
  • Differentiate among the immunoglobulin therapies available for the treatment of PI in order to provide patients with optimal, personalized care
  • Implement multidisciplinary, team-based strategies and shared decision-making to optimize quality of care and outcomes for individuals with PI

Financial Support

Supported by educational grants from Grifols and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Pediatricians, immunologists, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists 

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-25-105-H01-P).

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.00 Contact Hours.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 11/18/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Azar reports the following financial relationships:

Consultant: ADMA Biologics, Inc.; argenx; CSL; Octapharma USA, Inc.; and Takeda Pharmaceutical Company Limited

Grants: Grifols and Octapharma USA, Inc.

Speakers Bureau: Grifols and Takeda Pharmaceutical Company Limited

Dr. Ballow reports the following financial relationships:

Advisory Board and Consultant: CSL Behring

Speakers Bureau: ADMA and CSL Behring

Other financial or material support: Atlantic Pharma – Data Safety Monitoring Board (DSMB); Immune Deficiency Foundation (Consulting Medical Director); Pharming (DSMB); and Syneos Health (DSMB)

Planner

Ms. Jacqueline reports the following financial relationships:

Consultant/Brand Collaborations (ended 2024): Cefaly and Neura Health

Employment: Meraki Social

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Warren Beckman (Planning Committee)
Leah Zadrozny, DVM, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-287-111825-90

The Changing Face of Primary Immunodeficiency: Improving Diagnosis and Access to Treatment for All Patients
Event Date: 11/18/2025